BUDGET IMPACT OF ORAL NIRMATRELVIR/RITONAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN THE US

被引：0
|
作者：
Sandin, R. [1 ]
Veenstra, D. [2 ]
Dzingina, M. [3 ]
Vankelegom, M. [4 ]
Sullivan, S. [2 ]
Campbell, D. [5 ]
Ma, C. [4 ]
Harrison, C. [4 ]
Draica, F. [6 ]
Wiemken, T. L. [6 ]
Mugwagwa, T. [6 ]
机构：
[1] Pfizer AB, Stockholm, Sweden
[2] Curta Inc, Seattle, WA USA
[3] Pfizer, London, England
[4] Hlth Econ & Outcomes Res Ltd, Cardiff, Wales
[5] Curta Inc, S Kingstown, RI USA
[6] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE644
引用
收藏
页码：S177 / S177
页数：1
相关论文
共 50 条
  • [41] Safety, efficacy, and pharmacokinetics of nirmatrelvir and ritonavir in patients with severe COVID-19 and renal impairment: A case report
    Zheng, Ren
    Fan, Xudong
    Zhou, Feng
    Ye, Xiqian
    Sun, Jing
    Cheng, Junjie
    Yuan, Yuan
    Wang, Yu
    Cai, Xinjun
    Wei, Anqi
    HELIYON, 2024, 10 (06)
  • [42] Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews
    Cruciani, Mario
    Pati, Ilaria
    Masiello, Francesca
    Pupella, Simonetta
    De Angelis, Vincenzo
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (03) : 477 - 497
  • [43] Real-World Effectiveness of Nirmatrelvir-Ritonavir and Its Acceptability in High-Risk COVID-19 Patients
    Kim, Min-Kyung
    Lee, Kyung-Shin
    Ham, Sin Young
    Choi, Youn Young
    Lee, Eunyoung
    Lee, Seungjae
    Lee, Bora
    Jeon, Jaehyun
    Chin, Bumsik
    Kim, Yeonjae
    Kim, Gayeon
    Jang, Hee -Chang
    Choi, Jae-Phil
    Park, Sang -Won
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2023, 38 (35)
  • [44] Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
    Reis, Stefanie
    Metzendorf, Maria-Inti
    Kuehn, Rebecca
    Popp, Maria
    Gagyor, Ildiko
    Kranke, Peter
    Meybohm, Patrick
    Skoetz, Nicole
    Weibel, Stephanie
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (09): : CD015395
  • [45] Nirmatrelvir/ritonavir treatment and risk for postacute sequelae of COVID-19 in older Singaporeans
    Wee, Liang En
    Lim, Jue Tao
    Tay, An Ting
    Chiew, Calvin J.
    Young, Barnaby Edward
    Wong, Betty
    Lim, Ruth
    Li Lee, Ching
    Tan, Joyce
    Vasoo, Shawn
    Lye, David Chien
    Tan, Kelvin Bryan
    CLINICAL MICROBIOLOGY AND INFECTION, 2025, 31 (01) : 93 - 100
  • [46] Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19
    Reddy, Gangireddy Navitha
    Jogvanshi, Akanksha
    Naikwadi, Sana
    Sonti, Rajesh
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2023, 21 (09) : 943 - 955
  • [47] Nirmatrelvir-ritonavir (Paxlovid®), a treatment for Covid-19
    Buxeraud, Jacques
    Faure, Sebastien
    Fougere, Edouard
    ACTUALITES PHARMACEUTIQUES, 2020, 61 (617): : 10 - 12
  • [48] Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD
    Hiremath, Swapnil
    McGuinty, Michaeline
    Argyropoulos, Christos
    Brimble, K. Scott
    Brown, Pierre Antoine
    Chagla, Zain
    Cooper, Rebecca
    Hoar, Stephanie
    Juurlink, David
    Treleaven, Darin
    Walsh, Michael
    Yeung, Angie
    Blake, Peter
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (08): : 1247 - 1250
  • [49] Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications
    Dormuth, Colin R.
    Kim, Jason D.
    Fisher, Anat
    Piszczek, Jolanta
    Kuo, I. Fan
    JAMA NETWORK OPEN, 2023, 6 (10) : E2336678
  • [50] VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19
    Cao, Zhujun
    Gao, Weiyi
    Bao, Hong
    Feng, Haiyan
    Mei, Shuya
    Chen, Peizhan
    Gao, Yueqiu
    Cui, Zhilei
    Zhang, Qin
    Meng, Xianmin
    Gui, Honglian
    Wang, Weijing
    Jiang, Yimei
    Song, Zijia
    Shi, Yiqing
    Sun, Jing
    Zhang, Yifei
    Xie, Qing
    Xu, Yiping
    Ning, Guang
    Gao, Yuan
    Zhao, Ren
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (05): : 406 - 417
12345